Aspen Pharma Revenue and Competitors
Estimated Revenue & Valuation
- Aspen Pharma's estimated annual revenue is currently $200M per year.
- Aspen Pharma's estimated revenue per employee is $201,000
Employee Data
- Aspen Pharma has 995 Employees.
- Aspen Pharma grew their employee count by -3% last year.
Aspen Pharma's People
Name | Title | Email/Phone |
---|
Aspen Pharma Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $62.9M | 313 | 8% | N/A | N/A |
#2 | $26.5M | 132 | 7% | N/A | N/A |
#3 | $20.5M | 102 | 0% | N/A | N/A |
#4 | $18.3M | 91 | 6% | N/A | N/A |
#5 | $18.7M | 93 | 2% | N/A | N/A |
#6 | $72.2M | 359 | 6% | N/A | N/A |
#7 | $55.3M | 275 | 6% | N/A | N/A |
#8 | $35.8M | 178 | 6% | N/A | N/A |
#9 | $31M | 154 | 4% | N/A | N/A |
#10 | $70.8M | 352 | 5% | N/A | N/A |
What Is Aspen Pharma?
Aspen Pharma Australia commenced operations in May 2001. Besides marketing and distributing products owned by the Aspen Group, we also license in products from other companies, and are focused on meeting the needs of our licensors. We have a pipeline of products which we plan to launch in Australia. Our partners and licensors include the biggest names in the pharmaceutical industry, including CSL, Sanofi-Aventis, GlaxoSmithKline, Novartis, Eli Lilly, Abbott, Teva, MSD.
keywords:N/AN/A
Total Funding
995
Number of Employees
$200M
Revenue (est)
-3%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Aspen Pharma News
Dr. Helen Zidon is the Head of Medical Information at Aspen Pharma Group, where she oversees the medical information functions of Aspen...
ASKA Pharmaceutical Co., Ltd. Aspen Pharmacare Holdings Limited. AstraZeneca Plc. Baxter International Inc. Dr. Reddy's Laboratories Limited.
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $354.9M | 998 | -30% | N/A |
#2 | $308.3M | 1001 | 6% | N/A |
#3 | $75M | 1002 | 9% | N/A |
#4 | $252.8M | 1003 | 21% | N/A |
#5 | $252.8M | 1003 | 7% | N/A |